Ignite Creation Date:
2024-10-26 @ 3:42 PM
Last Modification Date:
2024-10-26 @ 3:42 PM
Study NCT ID:
NCT06629688
Status:
COMPLETED
Last Update Posted:
None
First Post:
2024-10-02
Brief Title:
The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus
Sponsor:
None
Organization:
None
Study Overview
Official Title:
The Effect of Parenterally Administred Semaglutide on Intestinal Iron Absorption in Individuals With Type 2 Diabetes Mellitus
Status:
COMPLETED
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Semaglutide belongs to a group of long-acting glucagon-like peptide 1 receptor agonists GLP-1 Disorders in iron absorption have been linked to numerous medication dietary and nutrient interactions thus far The study aimed to determine whether there is an effect of concomitant parenteral administration of semaglutide and oral iron preparations on iron absorption in patients with type 2 diabetes T2DM
Detailed Description:
Type 2 diabetes mellitus T2DM affects over 537 million people worldwide making it a major chronic and progressive health problem among adults Novel approaches to managing T2DM have been developed as a result of medical advancements Glucagon-like peptide-1 receptor agonists GLP-1 RAs are appealing options for the treatment of T2DM since they efficiently reduce body weight and haemoglobin A1C with a minimal risk of hypoglycaemia
Semaglutide a long-acting GLP-1 RA has a very high structural homology with endogenous GLP-1 high binding affinity to albumin and resistance to degradation by the intestinal enzyme dipeptidyl peptidase-4 Because of these characteristics and his extended half-life it can be used once weekly Similar to all other GLP-1 RAs semaglutide decreases gastrointestinal motility and slows stomach emptying Delay in stomach emptying and intestinal motility can interfere with vitamin mineral and drug absorption Iron is one of the essential micronutrients in the human body On average 10 - 20 mg of iron is consumed daily through food but only 1 - 2 mg of iron is absorbed in the duodenum and the first section of the small intestine It has been shown that drugs which decrease gastrointestinal motility can interfere with iron absorption However the relationship between parenteral semaglutide administration and intestine iron absorption has not been the subject of any prior studies Thus this study aimed to determine whether there is an effect of parenteral administration of semaglutide on iron absorption in patients with T2DM
Semaglutide a long-acting GLP-1 RA has a very high structural homology with endogenous GLP-1 high binding affinity to albumin and resistance to degradation by the intestinal enzyme dipeptidyl peptidase-4 Because of these characteristics and his extended half-life it can be used once weekly Similar to all other GLP-1 RAs semaglutide decreases gastrointestinal motility and slows stomach emptying Delay in stomach emptying and intestinal motility can interfere with vitamin mineral and drug absorption Iron is one of the essential micronutrients in the human body On average 10 - 20 mg of iron is consumed daily through food but only 1 - 2 mg of iron is absorbed in the duodenum and the first section of the small intestine It has been shown that drugs which decrease gastrointestinal motility can interfere with iron absorption However the relationship between parenteral semaglutide administration and intestine iron absorption has not been the subject of any prior studies Thus this study aimed to determine whether there is an effect of parenteral administration of semaglutide on iron absorption in patients with T2DM
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None